Real-World Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from Longitudinal Analyses in 6- and 12-month Cohorts From the PPD CorEvitas Atopic Dermatitis Registry

Abstract

Introduction: Clinical trials previously established the short and long-term efficacy and safety of upadacitinib (UPA) for the treatment of atopic dermatitis (AD). Here we report 12-month real-world effectiveness of UPA in adults from the PPD™ CorEvitas™ AD Registry.

Materials and Methods The PPD™ CorEvitas™ AD Registry is a prospective, non-interventional registry of adults with AD in the US and Canada. Participants in this analysis were enrolled through May 30, 2025, with data available for the baseline and 12-month follow up visit, at which they were receiving UPA treatment. We report on achievement of validated Investigators Global Assessment Scale for AD of “clear” or “almost clear” (vIGA-AD 0/1) for participants with a score ≥2 at baseline, improvement of ≥90%/100% from baseline in Eczema Area and Severity (EASI 90/100), Peak Pruritus Numeric Rating Scale PP-NRS score of 0 or 1 for participants with a baseline score ≥1 (PP-NRS 0/1; little-to-no itch), Dermatology Life Quality Index score  of 0 or 1 for participants with a baseline score ≥1 (DLQI 0/1; no effect on quality of life [QoL]), and simultaneous achievement of EASI 90 + PP-NRS 0/1. Proportions are reported as observed with no imputation. Safety was not assessed in this analysis.

Results A total of 189 participants were included in the 12-month analysis (mean age at baseline 47.2 years, 53.4% female, and 39.7% had prior biologic experience). Most participants (65.5%, 114/174) achieved vIGA-AD 0/1, and EASI 90 (62.2%; 112/180); nearly half (48.9%; 88/180) achieved EASI 100. Many participants reported little-to-no itch (41.4%; 70/169) and no effect of AD on QoL (44.6%; 78/175). Over one-third (37.9%; 61/161) of participants achieved simultaneous EASI 90 + PP-NRS 0/1. These results are comparable with the results of a separate 6-month visit cohort analysis.

Conclusion In a real-world setting, many patients with 12 months of treatment with upadacitinib reported little-to-no itch, clear or almost clear skin, including simultaneous achievement of skin clearance and itch relief, and no impact of AD on their QoL. The comparable achievement of optimal treatment targets at 6- and 12-months underscore UPA long-term consistency and effectiveness in AD treatment.